Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Main Purpose of this study is to determine the efficacy and safety of Cadonilimab combined with chemotherapy (cisplatin) for locally advanced cervical cancer. This is an multicentre, single Arm, Phase 2 Trial study of Cadonilimab with Cisplatin in the treatment of locally advanced cervical cancer. 29 eligible patients will receive Cadonilimab（10mg/kg, iv., D1, q3w）with Cisplatin ( 75mg/ m2, iv., D2， q3w) for a total of 2-4 cycles before radical surgical treatment.

NCT Number	NCT07104149
Lead Sponsor	The First Affiliated Hospital of Zhengzhou University Collaborators: Second Affiliated Hospital of Zhengzhou University, Henan Provincial People's Hospital
Conditions	Female, Age ≥ 18 Years Old, No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy, ECOG Score of 0-1, Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable Lesion, Sufficient Organ Function, The Result of the Urine or Serum Pregnancy Test for the Subject is Negative, Subjects Should Take Contraceptive Measures, Locally Advanced Cervical Cancer +1 more
Enrollment	29 participants
Start Date	2025-03-10
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-08-05